Recent Finacing
Recent Raise
Adamas Pharmaceuticals develops TCAD antiviral therapies targeting multiple influenza strains, including resistant variants, conducting phase‑2 southern‑hemisphere trials and planning North American studies with the U.S. Navy.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors